### Guideline Page and Request

#### WM/LPL-B (1 of 2)

**Internal request:**
In response to the publication of the iNNOVATE trial and subsequent FDA approval of ibrutinib + rituximab in patients with previously untreated WM

**External request:**
Submission from Pharmacyclics, LLC and Janssen Biotech, Inc. to add ibrutinib + rituximab for primary therapy for WM/LPL patients as a Preferred Regimen with Category 1 evidence rating.

**Panel Discussion/References**
- Based on the data in the noted reference, the panel consensus was to include ibrutinib + rituximab as an Other Recommended Regimen for primary therapy.
  - The panel consensus was that the data does not support a category 1 recommendation. This was added as a category 2A recommendation.

**Institution Vote**

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>Abstain</th>
<th>Absent</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
<td>0</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>13</td>
<td>4</td>
<td>1</td>
<td>5</td>
</tr>
</tbody>
</table>

**Reference**

#### WM/LPL-B (2 of 2)

**Internal Request:**
In response to the publication of the iNNOVATE trial and subsequent FDA approval of ibrutinib + rituximab for relapsed/refractory WM

**External request:**
Submission from Pharmacyclics, LLC and Janssen Biotech, Inc. to add ibrutinib + rituximab for Previously Treated WM/LPL patients as a Preferred Regimen with Category 1 evidence rating.

**Panel Discussion/References**
- Based on the data in the noted reference, the panel consensus was to include ibrutinib + rituximab as a Preferred Regimen for previously treated WM/LPL.
  - The panel consensus was that the data does not support a category 1 recommendation. This was added as a category 2A recommendation.

**Institution Vote**

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>Abstain</th>
<th>Absent</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
<td>0</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>13</td>
<td>4</td>
<td>1</td>
<td>5</td>
</tr>
</tbody>
</table>

**Reference**